Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Advisory - Health Canada seized three unauthorized eye drop products from Floy Beauty stores in Toronto, Ontario, because they may pose serious health risks


OTTAWA, Dec. 20, 2019 /CNW/ - Health Canada is advising consumers that it has seized three unauthorized eye drop products from two Floy Beauty stores in Toronto, Ontario, because they may pose serious health risks. The seized products are Santen Sante FX Neo, Santen Sante FX V+, and Santen Sante Antibacterial Eye Drops.

According to the product labels, these products contain prescription drugs. Prescription drugs should be taken only under the advice and supervision of a healthcare professional because they are used to treat specific conditions and may cause serious side effects.

Selling unauthorized health products in Canada is illegal. Health products that have not been authorized by Health Canada have not been assessed for safety, effectiveness and quality, and may pose serious health risks. For example, unauthorized health products may be contaminated, may contain dangerous ingredients not listed on the label, or may not contain the ingredients shown on the label.

Who is affected

Consumers who have bought or are using the affected products.

Affected products

 

Product

Risk

Retail Location

Santen Sante FX Neo

Labelled to contain neostigmine methylsulfate and aminocaproic acid

Floy Beauty

5 Northtown Way

Toronto, ON

 

Floy Beauty

4750 Yonge Street, Unit 147

North York, ON

Santen Sante FX V+

Labelled to contain neostigmine methylsulfate and aminocaproic acid

Floy Beauty

5 Northtown Way

Toronto, ON

 

Floy Beauty

4750 Yonge Street, Unit 147

North York, ON

Santen Sante Antibacterial Eye Drops

Labelled to contain sulfamethoxazole

Floy Beauty

5 Northtown Way

Toronto, ON

 

What consumers should do

Background

Aminocaproic acid: This is a prescription drug ingredient used to decrease bleeding in various clinical situations. Exposure to aminocaproic acid in the eye may affect the eye itself and the acid may be absorbed through the tear ducts into the blood. Side effects may include watery eyes, vision changes, headache, dizziness, nausea, muscle weakness and skin rash.

Neostigmine methylsulfate: There are no approved eye drops containing neostigmine methylsulfate on the Canadian market. In the past, drugs similar to neostigmine were used to treat glaucoma. These medications are no longer widely used because of the significant number of potential eye-related side effects, including blurred distance vision, frontal headaches, twitching lids, red eyes, cataracts, allergic reactions, iris cysts, retinal detachment and the potential for causing a specific type of glaucoma attack. In addition, absorption into the nose via the tear duct may cause serious cardiac and respiratory side effects.

Sulfamethoxazole: This is a prescription sulfa-containing antibiotic drug, normally taken by mouth to treat bacterial infections in the bladder, lungs and gastrointestinal tract. There are no eye drops containing sulfamethoxazole authorized by Health Canada. When taken by mouth, rare side effects can include death due to severe blistering skin reactions (Stevens-Johnson Syndrome and toxic epidermal necrolysis), liver failure, kidney failure, failure to produce blood cells, and allergic reactions in the lungs. Common side effects may include nausea and vomiting, diarrhea, headache, rash, fatigue, nosebleeds, hair loss and thrush. Sulfa-containing drugs should not be used in women who are pregnant or breastfeeding and in infants under two months of age.

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 17:55
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...

at 17:20
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...

at 17:00
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...

at 16:19
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....



News published on and distributed by: